UI Cancer Center members invited to submit clinical trial ideas

UI Cancer Center members invited to submit clinical trial ideas

University of Illinois Cancer Center members are invited to submit ideas for early-phase clinical trials in cancer prevention to the Northwestern Cancer Prevention Consortium (NCPC), in which the UI Cancer Center is a member.

The NCPC, which includes 15 institutional members, is one of three academic consortia that were recently approved for funding by the National Cancer Institute, Division of Cancer Prevention (NCI/DCP). These consortia comprise the newly-created Cancer Prevention Clinical Trials Network (CP-CTNet). The funding provides infrastructure and administrative support for investigator-initiated – as well as NCI-solicited – Phase 0-II biomarker-based primary prevention trials. This support includes assistance with proposal development, biospecimen management, statistical analysis and recruitment. Eligible trials should have a sample size under ~120, with a budget under $1 million.

For cancer prevention researchers, this NCI/DCP program offers unique advantages over other funding mechanisms for the conduct of early-phase trials. The applicant pool is restricted, so the success rate is far higher than through other mechanisms. Between 2012 and 2017, 59% of NCPC’s proposals were funded, compared to only 12% for unsolicited R01 proposal submissions.

NCI/DCP outlined a number of areas of emphasis for the CP-CTNet. Trials addressing these topics are more likely to be funded:

  • Immunoprevention
  • Alternative/intermittent dosing regimens
  • Obesity-diabetes connection
  • Targeting multiple chronic diseases
  • Localized therapies
  • Innovative agents (molecularly targeted agents, repurposing “old” drugs)
  • Innovative early-phase trial designs (e.g., gene expression analysis)

To learn more, contact Maarten Bosland, DVSc, PhD, professor of pathology, University of Illinois at Chicago, College of Medicine, at boslandm@uic.edu.

Leave a Reply